Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens — SCULPTURE

Moderate to Severe Plaque-type Psoriasis Clinical Trial

Official title:
A Randomized, Double-blind, Multicenter Study of Subcutaneous Secukinumab, Assessing Psoriasis Area and Severity Index (PASI) Response and Maintenance of Response in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis on Either a Fixed Dose Regimen or on a Retreatment at Start of Relapse Regimen

Status Completed

Clinical Trial Summary

This study will assess the safety and efficacy of two different doses and two different dose regimens of subcutaneous secukinumab in patients that have moderate to severe, chronic, plaque-type psoriasis.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Moderate to Severe Plaque-type Psoriasis
Psoriasis

Clinical Trial Details

NCT number	NCT01406938
Study type	Interventional
Source	Novartis
Contact
Status	Completed
Phase	Phase 3
Start date	August 2011
Completion date	May 2013

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01555125` - First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks	Phase 3
Completed	`NCT01365455` - Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year	Phase 3
Completed	`NCT01544595` - Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab	Phase 3
Completed	`NCT02474069` - Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis	Phase 3